Workflow
Arbutus Biopharma(ABUS)
icon
Search documents
Arbutus Biopharma(ABUS) - 2023 Q3 - Earnings Call Transcript
2023-11-07 16:06
Arbutus Biopharma Corporation. (NASDAQ:ABUS) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO and CAO Karen Sims - Chief Medical Officer Michael Sofia - Chief Scientific Officer Michael McElhaugh - Chief Operating Officer Conference Call Participants Roy Buchanan - JMP Operator Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update C ...
Arbutus Biopharma(ABUS) - 2023 Q3 - Quarterly Report
2023-11-06 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State ...
Arbutus Biopharma(ABUS) - 2023 Q2 - Earnings Call Presentation
2023-08-10 13:08
Corporate Presentation NASDAQ: ABUS www.arbutusbio.com August 3, 2023 ...
Arbutus Biopharma(ABUS) - 2023 Q2 - Earnings Call Transcript
2023-08-03 19:18
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Conference Call August 3, 2023 8:45 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO Karen Sims - VP of Clinical Development Michael Sofia - Chief Scientific Officer Conference Call Participants Roy Buchanan - JMP Dennis Ding - Jefferies Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Q2 Conference Call. [Operator Instructions] Please be advised ...
Arbutus Biopharma(ABUS) - 2023 Q2 - Quarterly Report
2023-08-02 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or Ot ...
Arbutus Biopharma (ABUS) Investor Presentation - Slideshow
2023-05-18 15:23
| --- | --- | --- | --- | |--------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Corporate | | | | | | | | | | Presentation | | | | | | | | | | NASDAQ: ABUS | | | | | www.arbutusbio.com | | | | | May 4, 2023 | | | | © 2023 Arbutus Biopharma, Inc. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical f ...
Arbutus Biopharma(ABUS) - 2023 Q1 - Earnings Call Transcript
2023-05-04 18:54
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2023 Results Conference Call May 4, 2023 8:45 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO and CAO Karen Sims - VP of Clinical Development Michael Sofia - Chief Scientific Officer Conference Call Participants Thomas Yip - H.C. Wainwright Roy Buchanan - JMP Dennis Ding - Jefferies Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2023 First Quarter Financial ...
Arbutus Biopharma(ABUS) - 2023 Q1 - Quarterly Report
2023-05-03 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or O ...
Arbutus Biopharma (ABUS) Investor Presentation - Slideshow
2023-03-07 18:58
Corporate Presentation NASDAQ: ABUS www.arbutusbio.com March 2, 2023 © 2023 Arbutus Biopharma, Inc. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the potential market opportunity for HBV; Arbutus' abili ...
Arbutus Biopharma(ABUS) - 2022 Q4 - Earnings Call Transcript
2023-03-02 16:39
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2022 Earnings Conference Call March 2, 2023 8:45 AM ET Company Participants Lisa Caperelli - VP of IR William Collier - President and CEI Michael Sofia - Chief Scientific Officer David Hastings - CFO Michael McElhaugh - COO Conference Call Participants Dennis Ding - Jefferies Charles Moore - Baird Thomas Yip - H.C. Wainwright Keay Nakae - Chardan Roy Buchanan - JMP Securities Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Co ...